12/4
07:20 pm
idya
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance [Yahoo! Finance]
Low
Report
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance [Yahoo! Finance]
12/4
07:00 pm
idya
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Low
Report
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
12/4
07:00 pm
idya
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
Low
Report
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
12/1
06:00 am
idya
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
Medium
Report
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
11/30
02:17 am
idya
A Closer Look at IDEAYA Biosciences (IDYA) Valuation as Investor Optimism Builds [Yahoo! Finance]
Medium
Report
A Closer Look at IDEAYA Biosciences (IDYA) Valuation as Investor Optimism Builds [Yahoo! Finance]
11/28
06:34 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/28
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
11/25
05:01 pm
idya
Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away [Seeking Alpha]
Low
Report
Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away [Seeking Alpha]
11/24
09:04 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) was given a new $59.00 price target on by analysts at Truist Financial Corporation.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) was given a new $59.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/24
06:00 am
idya
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
Low
Report
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
11/12
05:56 pm
idya
WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight [Yahoo! Finance]
Low
Report
WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight [Yahoo! Finance]
11/11
09:06 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its price target raised by analysts at Mizuho from $44.00 to $46.00. They now have an "outperform" rating on the stock.
Medium
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its price target raised by analysts at Mizuho from $44.00 to $46.00. They now have an "outperform" rating on the stock.
11/9
01:13 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) was upgraded by analysts at
Wall Street
Medium
Report
IDEAYA Biosciences (NASDAQ:IDYA) was upgraded by analysts at
Wall Street
11/4
06:00 am
idya
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
10/31
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/27
06:00 am
idya
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
High
Report
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
10/23
12:32 pm
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its price target raised by analysts at JPMorgan Chase & Co. from $74.00 to $79.00. They now have an "overweight" rating on the stock.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its price target raised by analysts at JPMorgan Chase & Co. from $74.00 to $79.00. They now have an "overweight" rating on the stock.
10/21
09:04 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
10/21
09:04 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) was given a new $30.00 price target on by analysts at New Street Research.
Medium
Report
IDEAYA Biosciences (NASDAQ:IDYA) was given a new $30.00 price target on by analysts at New Street Research.
10/21
08:24 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its price target raised by analysts at Royal Bank Of Canada from $38.00 to $41.00. They now have an "outperform" rating on the stock.
Medium
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its price target raised by analysts at Royal Bank Of Canada from $38.00 to $41.00. They now have an "outperform" rating on the stock.
10/21
08:05 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $62.00 price target on the stock.
Medium
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $62.00 price target on the stock.
10/20
06:30 am
idya
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
Low
Report
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
10/20
06:00 am
idya
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
Low
Report
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
10/8
12:25 pm
idya
IDEAYA Biosciences (NASDAQ:IDYA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.